Generation of induced pluripotent stem cells from human blood

Loh, Yuin-Han; Agarwal, Suneet; Park, In‐Hyun; Urbach, Achia; Huo, Hongguang; Heffner, Garrett C.; Kim, Kitai; Miller, Joseph S.; Ng, Kelvin S.; Daley, George Q.

doi:10.1182/blood-2009-02-204800

Cited by 559 publications

(433 citation statements)

References 20 publications

(20 reference statements)

Supporting

Mentioning

424

Contrasting

Unclassified

Order By: Relevance

“…2 These genes were suppressed with the differentiation of hepatoma cells into hepatocytes by hepatocyte nuclear factor 4␣ (HNF4␣). 3 Therefore, it may be reasonable to hypothesize that down-regulation of these four genes might improve the efficacy of human HCC therapy as suggested by Dr Moriguchi. 1 2046…”

Section: Differentiation Therapy With Transcription Factors Might Prementioning

confidence: 99%

“…1 As a result, the gene expression levels of c-Myc and Klf4 were lower than that of Oct3/4 and Sox2 in human iPS cells. 2,3 However, the gene expression levels of c-Myc and Klf4 were higher than that of Oct3/4 and Sox2 in Hep3B and HepG2 human hepatoma cell lines. 1 On the other hand, the relative ratio of Oct3/4 and Sox2 was 1:1 in human iPS cells derived from neonatal foreskin fibroblasts, adult dermal fibroblasts, and CD 34ϩ mobilized human peripheral blood cells, generally.…”

mentioning

confidence: 97%

“…1 On the other hand, the relative ratio of Oct3/4 and Sox2 was 1:1 in human iPS cells derived from neonatal foreskin fibroblasts, adult dermal fibroblasts, and CD 34ϩ mobilized human peripheral blood cells, generally. 2,3 However, for example, the relative ratio of Oct3/4 and Sox2 was 4:1 in Hep3B or HepG2 cells, generally. 1 Thus, the gene expression levels of the four factors or the relative ratio of Oct3/4 and Sox2 in human hepatoma cells were inappropriate in comparison with the cases of human iPS cells.…”

mentioning

confidence: 97%

“…The study by Yin et al 1 showed that a differentiation therapy with hepatocyte nuclear factor 4 alpha induced the differentiation of hepatoma cells into hepatocytes by the dramatic decrease of gene expression of four transcription factors (Oct3/4 [octamer 3/octamer 4], Sox2 [sexdetermining region Y box 2], Klf4 [Kruppel-like factor 4], and c-Myc) which are known reprogramming factors. [2][3][4] The results by Yin et al 1 may be helpful in order to understand the differences between human induced pluripotent stem (iPS) cells and human hepatoma cells or to develop novel HCC therapy. Therefore, first, I reviewed the gene expression of the four factors between human iPS cells established from healthy humans by using the four factors 2,3 and human hepatoma cells.…”

mentioning

confidence: 99%

“…[2][3][4] The results by Yin et al 1 may be helpful in order to understand the differences between human induced pluripotent stem (iPS) cells and human hepatoma cells or to develop novel HCC therapy. Therefore, first, I reviewed the gene expression of the four factors between human iPS cells established from healthy humans by using the four factors 2,3 and human hepatoma cells. 1 As a result, the gene expression levels of c-Myc and Klf4 were lower than that of Oct3/4 and Sox2 in human iPS cells.…”

mentioning

confidence: 99%

See 4 more Smart Citations

The reprogramming factors of human somatic cells are novel targets for human hepatocellular carcinoma therapy

Moriguchi

2009

Hepatology

View full text Add to dashboard Cite

Section: Differentiation Therapy With Transcription Factors Might Prementioning

confidence: 99%

mentioning

confidence: 97%

mentioning

confidence: 97%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

The reprogramming factors of human somatic cells are novel targets for human hepatocellular carcinoma therapy

Moriguchi

2009

Hepatology

View full text Add to dashboard Cite

Induced Pluripotent Stem Cells

Wilson

2015

JAMA

View full text Add to dashboard Cite

tem cells are a distinct self-replenishing cell population whose primary function is to generate progeny that then develop into terminally differentiated cell types, such as a cardiomyocytes, neurons or photoreceptors. Tissuespecific adult stem cells, or progenitors, are committed to producing tissue or lineage-specific cells, whereas totipotent or pluripotent stem cells can give rise to any of the 200+ cell types of the body. There are two types of pluripotent stem cells defined by their tissue origin: 1) embryonic stem (ES) cells obtained from early embryos, typically at the blastula stage, and 2) induced pluripotent stem (iPS) cells derived through a reprogramming process whereby terminally differentiated somatic cells are reprogrammed or induced to a pluripotent state (Figure 1). Successful generation of human iPS cells was reported independently in 2007 by the research groups of Drs James Thomson and ShinyaYamanaka 1,2 . Both groups successfully identified a minimum number of nuclear factors that could reprogramme terminally differentiated fibroblasts to pluripotent cell lines by exogenously expressing distinct yet overlapping sets of genes: Yu and colleagues used Oct4, Sox2, Nanog and Lin28 by lentiviral gene transfer, while Yamanaka and colleagues employed Oct4, Sox2, Klf4 and c-Myc via retroviral gene transfer. These landmark studies were a significant advance over whole nucleus reprogramming 3 and have had several important consequences. Induced pluripotent stem cell technology does not require human embryos and thus circumvents the ethical issues associated with

show abstract

Re‐entering the pluripotent state from blood lineage: promises and pitfalls of blood reprogramming

Chen

Yao

et al. 2019

FEBS Letters

View full text Add to dashboard Cite

Edited by Catherine RobinBlood reprogramming, in which induced pluripotent stem cells (iPSCs) are derived from haematopoietic lineages, has rapidly advanced over the past decade. Since the first report using human blood, haematopoietic cell types from various sources, such as the peripheral bone marrow and cord blood, have been successfully reprogrammed. The volume of blood required has also decreased, from around tens of millilitres to a single finger-prick drop. Besides, while early studies were limited to reprogramming methods relying on viral integration, nonintegrating reprogramming systems for blood lineages have been subsequently established. Together, these improvements have made feasible the future clinical applications of blood-derived iPSCs. Here, we review the progress in blood reprogramming from various perspectives, including the starting materials and subsequent reprogramming strategies. We also discuss the downstream applications of blood-derived iPSCs, highlighting their clinical value in terms of disease modelling and therapeutic development.

show abstract

Generation of induced pluripotent stem cells from human blood

Cited by 559 publications

References 20 publications

The reprogramming factors of human somatic cells are novel targets for human hepatocellular carcinoma therapy

The reprogramming factors of human somatic cells are novel targets for human hepatocellular carcinoma therapy

Induced Pluripotent Stem Cells

Re‐entering the pluripotent state from blood lineage: promises and pitfalls of blood reprogramming

Contact Info

Product

Resources

About